[go: up one dir, main page]

YU2694A - Transdermalni terapeutski sistem za odavanje galantamina - Google Patents

Transdermalni terapeutski sistem za odavanje galantamina

Info

Publication number
YU2694A
YU2694A YU2694A YU2694A YU2694A YU 2694 A YU2694 A YU 2694A YU 2694 A YU2694 A YU 2694A YU 2694 A YU2694 A YU 2694A YU 2694 A YU2694 A YU 2694A
Authority
YU
Yugoslavia
Prior art keywords
therapeutic system
galantamine
transdermal therapeutic
administration
reservoir layer
Prior art date
Application number
YU2694A
Other languages
English (en)
Other versions
YU48607B (sh
Inventor
T. Hille
L. Deurer
Original Assignee
Lts Lohmann Therapie - Systeme Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie - Systeme Gmbh. & Co.Kg. filed Critical Lts Lohmann Therapie - Systeme Gmbh. & Co.Kg.
Publication of YU2694A publication Critical patent/YU2694A/sh
Publication of YU48607B publication Critical patent/YU48607B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na transdermalni terapeutski sistem (TTS) za odavanje galantamina na kožu sa jednim zadnjim slojem nepropustljivim za aktivnu supstancu i jednim adhezivnim lepljivim rezervoarskim sloje, pri čemu rezervoarski sloj obuhvata 40-80 mas.-% polimernog materijala, odabranog iz grupe poliakrilata, 0,1-30 mas.-56 omekšivača i O,1-30 mas.-% galantamin baze ili jedne njegove farmaceutski prihvatljive soli.
YU2694A 1993-01-23 1994-01-21 Transdermalni terapeutski sistem (tts) za odavanje galantamina YU48607B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301783A DE4301783C1 (de) 1993-01-23 1993-01-23 Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil

Publications (2)

Publication Number Publication Date
YU2694A true YU2694A (sh) 1996-10-18
YU48607B YU48607B (sh) 1998-12-23

Family

ID=6478781

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2694A YU48607B (sh) 1993-01-23 1994-01-21 Transdermalni terapeutski sistem (tts) za odavanje galantamina

Country Status (26)

Country Link
US (1) US5700480A (sh)
EP (1) EP0680325B1 (sh)
JP (1) JPH08505632A (sh)
KR (1) KR100300477B1 (sh)
AT (1) ATE216240T1 (sh)
AU (1) AU679032B2 (sh)
CA (1) CA2153572C (sh)
CZ (1) CZ287053B6 (sh)
DE (2) DE4301783C1 (sh)
DK (1) DK0680325T3 (sh)
ES (1) ES2176234T3 (sh)
FI (1) FI113744B (sh)
HR (1) HRP940028B1 (sh)
HU (1) HU221165B1 (sh)
IL (1) IL108235A (sh)
MY (1) MY109926A (sh)
NO (1) NO307497B1 (sh)
NZ (1) NZ259857A (sh)
PH (1) PH31473A (sh)
PL (1) PL175083B1 (sh)
PT (1) PT680325E (sh)
SI (1) SI9400024A (sh)
SK (1) SK281339B6 (sh)
WO (1) WO1994016707A1 (sh)
YU (1) YU48607B (sh)
ZA (1) ZA94414B (sh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429791C2 (de) * 1994-08-23 1997-04-24 Lohmann Therapie Syst Lts Medizinischer Haftkleber auf Basis von Polyacrylaten und dessen Verwendung
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU732803B2 (en) * 1996-01-17 2001-05-03 National Starch And Chemical Investment Holding Corporation Adhesives resistant to skin-penetration enhancers
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
ES2227707T3 (es) * 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
DE19649534B4 (de) * 1996-11-29 2004-05-06 Lts Lohmann Therapie-Systeme Ag Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern
DE19653605C2 (de) * 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
DK1140105T3 (da) * 1998-12-24 2004-02-23 Janssen Pharmaceutica Nv Galantaminpræparat med styret frigivelse
US6241998B1 (en) 1999-02-02 2001-06-05 Acutek International Dermatological patch
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
EP1221315A4 (en) * 1999-10-13 2007-12-12 Senju Pharma Co ADHESIVE OPHTHALMIC PREPARATIONS FOR PERCUTANEOUS SPREADING
MXPA02005667A (es) 1999-12-10 2004-09-10 Bonnie Davis Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
CN1293196C (zh) * 2000-05-26 2007-01-03 大日本住友制药株式会社 具有副作用降低的特性的新型重组腺病毒载体
FR2814368B1 (fr) * 2000-09-26 2004-05-07 Pf Medicament Preparation pharmaceutique a base d'oxans
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
EP1895994B1 (en) * 2005-05-13 2010-08-25 ALZA Corporation Multilayer drug delivery system with barrier against reservoir material flow
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
DE102008059054A1 (de) 2008-11-26 2010-05-27 Otto Bock Pur Life Science Gmbh Polyurethanpflaster für die transdermale Applikation von Wirkstoffen und Verfahren zu dessen Herstellung
BR112013012156A2 (pt) 2010-11-17 2017-12-05 Hexal Ag sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
KR101317158B1 (ko) * 2011-02-18 2013-10-15 조선대학교산학협력단 갈란타민 또는 그의 염을 함유하는 경피흡수제제
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285820B2 (ja) * 2014-08-07 2018-02-28 久光製薬株式会社 ガランタミン含有経皮吸収製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20180008612A1 (en) * 2016-07-11 2018-01-11 Taho Pharmaceuticals Ltd. Transdermal delivery system containing galantamine or salts thereof
JP7515582B2 (ja) 2019-11-06 2024-07-12 スマーテック トピカル，インコーポレイテッド シクロオキシゲナーゼ阻害剤の局所配合剤およびその使用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3843239C1 (sh) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
NZ242744A (en) * 1991-05-14 1997-02-24 Ernir Snorrason Use of a cholinesterase inhibitor (eg a galanthamine derivative) for treating fatigue

Also Published As

Publication number Publication date
HUT72643A (en) 1996-05-28
CZ184295A3 (en) 1996-01-17
NO952907L (no) 1995-07-21
AU5881794A (en) 1994-08-15
CA2153572A1 (en) 1994-08-04
IL108235A (en) 1996-10-31
HU9501928D0 (en) 1995-09-28
WO1994016707A1 (de) 1994-08-04
NO952907D0 (no) 1995-07-21
HU221165B1 (en) 2002-08-28
HRP940028A2 (en) 1996-06-30
KR100300477B1 (ko) 2001-10-22
CA2153572C (en) 2006-01-03
FI113744B (fi) 2004-06-15
US5700480A (en) 1997-12-23
SI9400024A (en) 1994-09-30
ATE216240T1 (de) 2002-05-15
MY109926A (en) 1997-09-30
YU48607B (sh) 1998-12-23
ES2176234T3 (es) 2002-12-01
EP0680325A1 (de) 1995-11-08
PH31473A (en) 1998-11-03
FI953533A0 (fi) 1995-07-21
DE4301783C1 (de) 1994-02-03
HRP940028B1 (en) 2000-02-29
IL108235A0 (en) 1994-04-12
CZ287053B6 (en) 2000-08-16
DE59410103D1 (de) 2002-05-23
SK281339B6 (sk) 2001-02-12
NO307497B1 (no) 2000-04-17
KR960700060A (ko) 1996-01-19
DK0680325T3 (da) 2002-08-05
JPH08505632A (ja) 1996-06-18
EP0680325B1 (de) 2002-04-17
SK88995A3 (en) 1996-05-08
AU679032B2 (en) 1997-06-19
FI953533L (fi) 1995-07-21
PL309603A1 (en) 1995-10-30
PL175083B1 (pl) 1998-10-30
PT680325E (pt) 2002-09-30
NZ259857A (en) 1996-03-26
ZA94414B (en) 1994-08-31

Similar Documents

Publication Publication Date Title
YU2694A (sh) Transdermalni terapeutski sistem za odavanje galantamina
YU226090A (sh) Postupak za izradu transdermalnog terapijskog sistema sa buprenorphinom kao aktivnim sastojkom
ES2152979T3 (es) Sistema terapeutico transdermal que contiene estradiol.
NO951523L (no) Plaster for transdermal administrering av flyktige, farmasöytisk aktive, kjemisk basiske bestanddeler, samt fremgangsmåte for fremstilling av plasteret
YU14394A (sh) Flaster sa aktivnom supstancom za davanje estradiola na kožu
DK1152751T3 (da) Transdermalt, terapeutisk desoxypeganinsysstem
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
YU47075B (sh) Postupak za izradu transdermalnog terapijskog sistema sa noepseudiefedrinom kao aktivnim sastojkom
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu
ES2172949T3 (es) Composiciones destinadas para la administracion transcutanea y cutanea de agentes biologicamente activos.